Results 91 to 100 of about 204,163 (273)

Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study [PDF]

, 2018
PURPOSE: To report preliminary results of induction chemotherapy (IC) followed by neoadjuvant chemoradiotherapy (CRT) and surgery in locally advanced rectal cancer (LARC) patients.MATERIALS AND METHODS: This is the preliminary evaluation of a phase II ...
Benevento, Ilaria, Bulzonetti, Nadia, Cortesi, Enrico, D'Ambrosio, Giancarlo, De Felice, Francesca, Iafrate, Franco, Iannitti, Marcella, Mancini, Marialaura, Marampon, Francesco, Marzo, Marco, Musio, Daniela, Tombolini, Vincenzo, Urbano, Federica   +12 more
core   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

Cancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang   +15 more
wiley   +1 more source

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial [PDF]

, 2014
Background: Central venous access devices in fluoropyrimidine therapy are associated with complications; however, reliable data are lacking regarding their natural history, associated complications and infusion pump performance in patients with ...
A Surov, AA Martoni, C Araújo, C Twelves, D Fagnani, D Haller, DC McGee, DZ Xiang, E Chu, E Chu, E McKenna, E Van Cutsem, EA Poplin, EB Lamont, F Ng, G Perrocheau, H-J Schmoll, I Kriegel, J Cassidy, J Cassidy, J Kawamura, J Shen-Gunther, L Cavanna, L Garrison, LB Saltz, M Gann Jr, M Karthaus, M Verso, M W Saif, MM Beckers, N Barbetakis, N Starling, P Debourdeau, R Biffi, S Lee, T Cartwright, T Conroy, The Meta-Analysis Group In Cancer, W Saber, W Scheithauer, W Sun, Y Inaba   +41 more
core   +2 more sources

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, EarlyView.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial

Journal of Antimicrobial Chemotherapy, 2018
Objectives To compare the efficacy of pre-emptive versus empirical antifungal therapy in children with cancer, fever and neutropenia. Methods This was a prospective, multicentre, randomized clinical trial.
M. Santolaya, A. Álvarez, Mirta Acuña, C. Avilés, C. Salgado, J. Tordecilla, M. Varas, Marcela Venegas, M. Villarroel, M. Zubieta, M. Farfán, V. de la Maza, Alejandra F. Vergara, R. Valenzuela, J. Torres   +14 more
semanticscholar   +1 more source

Carbapenems and febrile neutropenia [PDF]

Clinical Microbiology and Infection, 2017
International ...
Alfandari, S., Berthon, C., Ader, Florence   +2 more
openaire   +4 more sources

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, EarlyView.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK) [PDF]

Introduction: We report a cost-effectiveness evaluation of granulocyte colony-stimulating factors (G-CSFs) for prevention of febrile neutropenia (FN) following chemotherapy for non-Hodgkin’s lymphoma (NHL) in the United Kingdom (UK).
Akehurst, R., Cooper, K.L., Stevenson, M.D., Whyte, S.   +3 more
core   +3 more sources

Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53 Aberrations

European Journal of Haematology, EarlyView.
ABSTRACT The GAIA‐CLL13 trial showed that venetoclax‐obinutuzumab (Ven‐O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment‐naïve (TN) CLL patients. However, their higher costs warrant a cost‐effectiveness evaluation.
Lars Holger Ehlers, Mark‐David Levin, Marjolein van der Klift, Morten Berg Jensen, Hoa Thi Tuyet Tran, Arnon P. Kater, Carsten Utoft Niemann   +6 more
wiley   +1 more source

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. [PDF]

, 2018
BackgroundThe value of induction chemotherapy (ICT) remains under investigation despite decades of research. New advancements in the field, specifically regarding the induction regimen of choice, have reignited interest in this approach for patients with
Cohen, EEW, Haddad, RI, Hitt, R, Lefebvre, J-L, Posner, M, Schulten, J, Vermorken, JB   +6 more
core   +1 more source